Sterilizing Activity of Second-Line Regimens Containing TMC207 in a Murine Model of Tuberculosis
Open Access
- 3 March 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (3), e17556
- https://doi.org/10.1371/journal.pone.0017556
Abstract
The sterilizing activity of the regimen used to treat multidrug resistant tuberculosis (MDR TB) has not been studied in a mouse model. Swiss mice were intravenously inoculated with 6 log10 of Mycobacterium tuberculosis (TB) strain H37Rv, treated with second-line drug combinations with or without the diarylquinoline TMC207, and then followed without treatment for 3 more months to determine relapse rates (modified Cornell model). Bactericidal efficacy was assessed by quantitative lung colony-forming unit (CFU) counts. Sterilizing efficacy was assessed by measuring bacteriological relapse rates 3 months after the end of treatment. The relapse rate observed after 12 months treatment with the WHO recommended MDR TB regimen (amikacin, ethionamide, pyrazinamide and moxifloxacin) was equivalent to the relapse rate observed after 6 months treatment with the recommended drug susceptible TB regimen (rifampin, isoniazid and pyrazinamide). When TMC207 was added to this MDR TB regimen, the treatment duration needed to reach the same relapse rate dropped to 6 months. A similar relapse rate was also obtained with a 6-month completely oral regimen including TMC207, moxifloxacin and pyrazinamide but excluding both amikacin and ethionamide. In this murine model the duration of the WHO MDR TB treatment could be reduced to 12 months instead of the recommended 18–24 months. The inclusion of TMC207 in the WHO MDR TB treatment regimen has the potential to further shorten the treatment duration and at the same time to simplify treatment by eliminating the need to include an injectable aminoglycoside.Keywords
This publication has 30 references indexed in Scilit:
- Should Moxifloxacin Be Used for the Treatment of Extensively Drug-Resistant Tuberculosis? An Answer from a Murine ModelAntimicrobial Agents and Chemotherapy, 2010
- Bactericidal Potencies of New Regimens Are Not Predictive of Their Sterilizing Potencies in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2010
- Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Synergistic Activity of R207910 Combined with Pyrazinamide against Murine TuberculosisAntimicrobial Agents and Chemotherapy, 2007
- Evaluation of New Antituberculosis Drugs in Mouse ModelsAntimicrobial Agents and Chemotherapy, 2007
- Combinations of R207910 with Drugs Used To Treat Multidrug-Resistant Tuberculosis Have the Potential To Shorten Treatment DurationAntimicrobial Agents and Chemotherapy, 2006
- Global Incidence of Multidrug‐Resistant TuberculosisThe Journal of Infectious Diseases, 2006
- A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosisScience, 2005
- A Nonhuman Primate Model for Preclinical Testing of New Tuberculosis VaccinesClinical Infectious Diseases, 2000
- Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experimentsTubercle, 1991